Jens Kuhle

List of Publications by Year
in descending order

231 papers	15,628 citations	23567 58 h-index	21540 114 g-index
236 all docs	236 docs citations	236 times ranked	10961 citing authors

#	Article	IF	Citations
1	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	10.1	1,177
2	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science, 2022, 375, 296-301.	12.6	892
3	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
4	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
5	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1655-1661.	2.3	517
6	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
7	Neurofilament light chain. Neurology, 2015, 84, 2247-2257.	1.1	412
8	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
9	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology, 2019, 92, e1007-e1015.	1.1	346
10	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018, 141, 2382-2391.	7.6	345
11	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications, 2020, 11, 812.	12.8	316
12	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron, 2016, 91, 56-66.	8.1	289
13	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 371-378.	27.0	236
14	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
15	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	3.7	207
16	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nature Reviews Neurology, 2022, 18, 158-172.	10.1	205
17	Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Multiple Sclerosis Journal, 2016, 22, 1550-1559.	3.0	202
18	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197

#	ARTICLE	IF	CITATIONS
19	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	5.3	188
20	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology, 2017, 88, 826-831.	1.1	168
21	Neurofilaments: neurobiological foundations for biomarker applications. Brain, 2020, 143, 1975-1998.	7.6	167
22	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology, 2015, 84, 1639-1643.	1.1	153
23	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
24	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 678-686.	3.0	148
25	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
26	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	1.9	144
27	Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology, 2017, 89, 2108-2114.	1.1	139
28	Serum neurofilament light. Neurology, 2018, 91, e1338-e1347.	1.1	137
29	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurology, 2020, 77, 58.	9.0	135
30	Gut microbiota–specific IgA $^{+}$ B cells traffic to the CNS in active multiple sclerosis. Science Immunology, 2020, 5, .	11.9	132
31	Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e244.	6.0	129
32	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359.	9.0	129
33	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology, 2019, 93, e1299-e1311.	1.1	129
34	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Annals of Clinical and Translational Neurology, 2020, 7, 139-143.	3.7	126
35	A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis Journal, 2013, 19, 1597-1603.	3.0	122
36	CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Annals of Clinical and Translational Neurology, 2015, 2, 748-755.	3.7	118

#	ARTICLE	IF	CITATIONS
37	Neurofilament light chain serum levels correlate with 10‑year \<scp\>MRI\</scp\> outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1478-1491.	3.7	115
38	Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e422.	6.0	107
39	Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Multiple Sclerosis Journal, 2020, 26, 210-219.	3.0	105
40	The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?. Multiple Sclerosis and Related Disorders, 2018, 25, 112-121.	2.0	104
41	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.1	100
42	Prodromal symptoms of multiple sclerosis in primary care. Annals of Neurology, 2018, 83, 1162-1173.	5.3	98
43	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 565-573.	1.9	91
44	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
45	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.1	88
46	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
47	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.1	85
48	Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. Journal of Neurology, 2020, 267, 3476-3478.	3.6	83
49	Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. Journal of Stroke, 2018, 20, 228-238.	3.2	82
50	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	3.3	81
51	A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. Journal of Neuroimmunology, 2010, 220, 114-119.	2.3	80
52	Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1202-1207.	1.9	76
53	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	6.9	73
54	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71

#	ARTICLE	IF	CITATIONS
55	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology, 2021, 89, 610-616.	5.3	68
56	Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1691-1699.	3.0	67
57	Serum neurofilament light chain levels associations with gray matter pathology: a 5â€year longitudinal study. Annals of Clinical and Translational Neurology, 2019, 6, 1757-1770.	3.7	66
58	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1270-1272.	1.9	65
59	Data quality evaluation for observational multiple sclerosis registries. Multiple Sclerosis Journal, 2017, 23, 647-655.	3.0	64
60	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
61	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
62	Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. Journal of Autoimmunity, 2018, 86, 39-50.	6.5	63
63	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis Journal, 2020, 26, 1670-1681.	3.0	61
64	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.1	61
65	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain, 2021, 144, 1684-1696.	7.6	61
66	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 187-194.	3.1	59
67	Multiple sclerosis registries in Europe â€" results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	3.0	58
68	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. Journal of Neurology, 2018, 265, 1618-1624.	3.6	58
69	Neurofilament levels are associated with bloodâ€"brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	3.0	55
70	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553.	1.1	54
71	Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. Journal of Neurology, 2007, 254, 160-168.	3.6	52
72	Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection. Cerebrovascular Diseases, 2015, 40, 222-227.	1.7	51

#	Article	IF	Citations
73	Reduced Plasma Levels of 25-Hydroxycholesterol and Increased Cerebrospinal Fluid Levels of Bile Acid Precursors in Multiple Sclerosis Patients. Molecular Neurobiology, 2017, 54, 8009-8020.	4.0	50
74	Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4[+]T Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2014, 2014, 1-11.	2.2	48
75	Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Annals of the Rheumatic Diseases, 2018, 77, 1093-1094.	0.9	48
76	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 777-785.	3.0	46
77	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960.	1.1	45
78	The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. BMC Neurology, 2018, 18, 111.	1.8	44
79	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	7.2	44
80	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Annals of Clinical and Translational Neurology, 2019, 6, 1081-1089.	3.7	43
81	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	43
82	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 52-60.	3.0	41
83	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	9.0	41
84	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	38
85	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 2016, 11, e0152347.	2.5	38
86	Factors influencing serum neurofilament light chain levels in normal aging. Aging, 2021, 13, 25729-25738.	3.1	38
87	MiR-126: a novel route for natalizumab action?. Multiple Sclerosis Journal, 2014, 20, 1363-1370.	3.0	36
88	Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. Journal of Psychiatric Research, 2021, 140, 141-148.	3.1	36
89	Temporal association of sNfL and gad–enhancing lesions in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 945-955.	3.7	35
90	A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. Swiss Medical Weekly, 2018, 148, w14623.	1.6	34

#	ARTICLE	IF	CITATIONS
91	Epstein-Barr–negative MS: a true phenomenon?. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e318.	6.0	33
92	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1355-1362.	3.0	32
93	Exploring the effect of vitamin D$_3$ supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1280-1287.	3.0	32
94	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1556-1564.	2.3	32
95	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
96	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
97	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
98	Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. Hypertension, 2018, 71, 1178-1184.	2.7	29
99	Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology, 2019, 93, e968-e974.	1.1	29
100	Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
101	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Multiple Sclerosis Journal, 2017, 23, 1600-1613.	3.0	28
102	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 50-55.	3.0	28
103	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2014-2022.	3.0	28
104	A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis. Annals of Neurology, 2022, 92, 486-502.	5.3	28
105	Natalizumab-induced POU2AF1/Spi-B upregulation. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e223.	6.0	27
106	Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1669-1677.	4.3	27
107	Ratio and index of Neurofilament light chain indicate its origin in Guillain–Barré Syndrome. Annals of Clinical and Translational Neurology, 2020, 7, 2213-2220.	3.7	27
108	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	27

#	ARTICLE	IF	CITATIONS
109	Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease. Journal of Stroke, 2020, 22, 369-376.	3.2	27
110	Serum neurofilament light chain is increased in hereditary spastic paraplegias. Annals of Clinical and Translational Neurology, 2018, 5, 876-882.	3.7	26
111	High serum neurofilament associates with diffuse white matter damage in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	25
112	Blood neurofilament light chain at the doorstep of clinical application. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e599.	6.0	24
113	Serum Neurofilament Levels in Children With Febrile Seizures and in Controls. Frontiers in Neuroscience, 2020, 14, 579958.	2.8	24
114	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
115	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study. BMC Medicine, 2021, 19, 38.	5.5	24
116	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
117	A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2019, 163, 241-246.	0.6	23
118	Vitamin D $_3$ supplementation and neurofilament light chain in multiple sclerosis. Acta Neurologica Scandinavica, 2020, 141, 77-80.	2.1	22
119	Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis. Journal of Neuroinflammation, 2020, 17, 293.	7.2	22
120	Serum neurofilament light chain and optical coherence tomography measures in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
121	Diabetes, Glycated Hemoglobin (<scp>HbA1c)</scp>, and Neuroaxonal Damage in Parkinson's Disease (<scp>MARK€PD Study</scp>). Movement Disorders, 2022, 37, 1299-1304.	3.9	22
122	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	3.7	21
123	Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. Multiple Sclerosis and Related Disorders, 2020, 42, 102148.	2.0	21
124	Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102810.	2.0	21
125	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
126	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21

#	Article	IF	Citations
127	Multiple Sclerosis and Antibodies against KIR4.1. New England Journal of Medicine, 2016, 374, 1496-1498.	27.0	20
128	De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1230-1239.	3.0	20
129	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, e1466-e1474.	1.1	20
130	Mass Cytometry of CSF Identifies an MS-Associated B-cell Population. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	19
131	Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). Parkinsonism and Related Disorders, 2021, 90, 44-48.	2.2	19
132	Development of an age-adjusted model for blood neurofilament light chain. Annals of Clinical and Translational Neurology, 2022, 9, 444-453.	3.7	19
133	Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e215.	6.0	18
134	Lymphocyte recovery after fingolimod discontinuation in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	18
135	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology, 2022, 13, 852563.	4.8	18
136	Blood Neurofilament Light in Progressive Multiple Sclerosis. Neurology, 2022, 98, .	1.1	18
137	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AAfatigue-metabolism nexus?. Journal of Clinical Lipidology, 2019, 13, 654-663.e1.	1.5	17
138	A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 953.	2.4	17
139	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. Multiple Sclerosis Journal, 2022, 28, 573-582.	3.0	17
140	NfL and pNfH are increased in Friedreich's ataxia. Journal of Neurology, 2020, 267, 1420-1430.	3.6	17
141	Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881456.	1.0	16
142	Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. Frontiers in Neurology, 2018, 9, 984.	2.4	16
143	Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis. Journal of Neurology, 2021, 268, 941-949.	3.6	16
144	Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. Critical Care, 2021, 25, 32.	5.8	16

#	ARTICLE	IF	CITATIONS
145	Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. Journal of Neurology, 2021, 268, 3969-3974.	3.6	16
146	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	5.3	16
147	The Refinement of Genetic Predictors of Multiple Sclerosis. PLoS ONE, 2014, 9, e96578.	2.5	15
148	Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. Epilepsy and Behavior, 2019, 101, 106432.	1.7	15
149	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102389.	2.0	15
150	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.7	15
151	Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 582-589.	1.9	15
152	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. Frontiers in Neuroscience, 2022, 16, 819010.	2.8	15
153	Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2019, 28, 17-25.	2.0	14
154	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	2.0	14
155	Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. Journal of Neurology, 2021, 268, 2570-2577.	3.6	14
156	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain Communications, 2021, 3, fcab084.	3.3	14
157	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. Journal of Neurology, 2020, 267, 192-202.	3.6	12
158	Growth differentiation factor 15 is increased in stable MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
159	Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet Journal of Rare Diseases, 2021, 16, 19.	2.7	12
160	NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Neurology, 2018, 91, 755-757.	1.1	11
161	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	3.6	11
162	Serum neurofilament light chain as outcome marker for intensive care unit patients. Journal of Neurology, 2021, 268, 1323-1329.	3.6	11

#	ARTICLE	IF	CITATIONS
163	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases. Expert Opinion on Medical Diagnostics, 2011, 5, 333-346.	1.6	10
164	PARP-1 deregulation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989460.	1.0	10
165	60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. Frontiers in Neurology, 2020, 11, 156.	2.4	10
166	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	3.6	10
167	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	3.0	10
168	Central nervous system atrophy predicts future dynamics of disability progression in a realâ€world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	3.3	10
169	Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypesÂof Parkinsonâ€™s disease in the MARK-PD study. Journal of Neural Transmission, 2022, 129, 295-300.	2.8	10
170	Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study. Frontiers in Neurology, 2020, 11, 735.	2.4	9
171	The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis. Brain Sciences, 2021, 11, 751.	2.3	9
172	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
173	Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Communications, 2021, 3, fcab240.	3.3	9
174	Ageâ€Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (<scp>MARKâ€PD</scp>). Movement Disorders, 2022, 37, 435-436.	3.9	9
175	Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. Frontiers in Neurology, 2020, 11, 973.	2.4	8
176	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
177	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. Multiple Sclerosis Journal, 2021, 27, 439-448.	3.0	8
178	Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis. European Journal of Neurology, 2021, 28, 901-909.	3.3	8
179	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 388-393.	2.0	8
180	Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210805.	3.5	8

#	Article	IF	Citations
181	Immunological Predictors of Dimethyl Fumarateâ€‘Induced Lymphopenia. Annals of Neurology, 2022, 91, 676-681.	5.3	8
182	Decreased neurofilament light chain levels in estriolâ€‘treated multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 1316-1320.	3.7	8
183	Hepatitis E virus infections in patients with MS on oral disease-modifying treatment. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e594.	6.0	7
184	Serum NfL levels should be used to monitor multiple sclerosis evolution â€“ Yes. Multiple Sclerosis Journal, 2020, 26, 17-19.	3.0	7
185	Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. Journal of Neurology, 2020, 267, 153-161.	3.6	7
186	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. Annals of Neurology, 2022, 91, 814-820.	5.3	7
187	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 972-977.	1.9	7
188	Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort â€“ a prospective cohort study. BMC Pregnancy and Childbirth, 2019, 19, 403.	2.4	6
189	Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	6
190	Increasing cancer risk over calendar year in people with multiple sclerosis: a caseâ€“control study. Journal of Neurology, 2021, 268, 817-824.	3.6	6
191	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	3.0	6
192	A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies. Frontiers in Neurology, 0, 13, .	2.4	6
193	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. Expert Opinion on Medical Diagnostics, 2011, 5, 393-410.	1.6	5
194	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. European Neurology, 2018, 80, 207-214.	1.4	5
195	Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. Journal of Psychosomatic Research, 2021, 144, 110402.	2.6	5
196	Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation. JCI Insight, 2022, 7, .	5.0	5
197	Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria. Scientific Reports, 2022, 12, .	3.3	5
198	Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2022, 65, 104016.	2.0	5

#	ARTICLE	IF	CITATIONS
199	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV. , 2017, 58, 5985.		4
200	Impact of complement activation on clinical outcomes in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 944-950.	3.7	4
201	GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation. Frontiers in Neuroscience, 2021, 15, 647535.	2.8	4
202	Microstructure-Weighted Connectomics in Multiple Sclerosis. Brain Connectivity, 2022, 12, 6-17.	1.7	4
203	GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology. NeuroImage: Clinical, 2021, 29, 102522.	2.7	4
204	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. Diagnostic and Prognostic Research, 2021, 5, 17.	1.8	4
205	Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. Frontiers in Immunology, 2021, 12, 811351.	4.8	4
206	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.6	3
207	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	3
208	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003). Brain and Behavior, 2021, 11, e01998.	2.2	3
209	The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102864.	2.0	3
210	Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110693.	1.0	3
211	Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome. Brain and Behavior, 2022, 12, e2494.	2.2	3
212	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	1.0	3
213	Comment: "If you can't measure it, you can't improve it"(Lord Kelvin). Neurology, 2016, 87, 1335-1335.	1.1	2
214	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies. Frontiers in Neuroscience, 2021, 15, 791670.	2.8	2
215	Increased Neurofilament Light Chain Is Associated with Increased Risk of Long-Term Mortality in Cerebral Small Vessel Disease. Journal of Stroke, 2022, 24, 296-299.	3.2	2
216	Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels. Multiple Sclerosis Journal, 2022, 28, 2081-2089.	3.0	2

#	Article	IF	Citations
217	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
218	Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy. Acta Neurologica Belgica, 2015, 115, 445-447.	1.1	1
219	P3â€251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2018, 14, P1170.	0.8	1
220	Serum neurofilament light chains in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e895.	6.0	1
221	Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients. Journal of Affective Disorders Reports, 2021, 4, 100095.	1.7	1
222	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. BMJ Neurology Open, 2021, 3, e000192.	1.6	1
223	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
224	ICâ€04â€02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETAâ€AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P7.	0.8	0
225	ICâ€Pâ€094: CROSSâ€SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P82.	0.8	0
226	O3â€12â€01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P914.	0.8	0
227	Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease. Lancet, The, 2020, 396, 990.	13.7	0
228	Crossâ€modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e045905.	0.8	0
229	Quantification of the Neurofilament Light Chain Protein by Single Molecule Array (Simoa) Assay. Neuromethods, 2021, , 223-233.	0.3	0
230	Reply to: Neurofilament Light Chain in Patients with <scp>COVID</scp>â€19 and Bacterial Pneumonia. Annals of Neurology, 2021, 90, 175-176.	5.3	0
231	Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain. Frontiers in Neurology, 0, 13, .	2.4	0